Bio News

Eli Lilly’s next-generation obesity drug retatrutide produced an average weight loss of 28.3% after 80 weeks in a phase 3 trial. However, the discontinuation rate due to adverse events in the highest-dose group was 11%, higher than the up to 7% reported for existing treatments. Overall efficacy, including participants who discontinued the trial, was 25%, making the high rate of adverse events a key challenge for commercialization.

BIOBOOK TEAM
biobookmedia@biobook.co.krCG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug
Biogen Signs $411 Million Deal With Trimtech for Neurodegenerative Diseases
AstraZeneca’s new myasthenia gravis drug cligepa approved in the U.S. and EU
Helus meets primary endpoint in phase 3 trial of depression drug candidate, with 7.6-point improvement over placebo